Kimberly-Clark is expected to report Q2 2026 revenue of $4.22 billion and EPS of $2.01, with shares trading at $109.31 compared to an average analyst target of $117.93. The primary metric investors are monitoring is organic sales growth, specifically whether the company can sustain positive volume-mix momentum as pricing power starts to normalize.
Investors are also focused on the pending $48.7 billion acquisition of Kenvue, which is expected to reshape the company into a high-margin consumer health powerhouse by late 2026. Management's ability to maintain guidance despite a $50 million headwind from a distribution center fire will be critical for sentiment.